Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent

References

• De Saint-Hubert M, Prinsen K, Mortelmans L, et al. Molecular imaging of cell death. Methods 2009;48:178–87
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Marysael T, Fonge H, et al. Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer 2012;131:E129–37
   PubMed Web of Science ®Google Scholar
• Marysael T, Bauwens M, Ni Y, et al. Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy. Invest New Drugs 2012;30:2132–40
   PubMed Web of Science ®Google Scholar
• Li J, Cona MM, Chen F, et al. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. Theranostics 2012;2:1010–19
   PubMed Web of Science ®Google Scholar
• Li J, Cona MM, Chen F, et al. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics 2012;3:127–37
   Web of Science ®Google Scholar
• Ni Y, Bormans G, Chen F, et al. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol 2005;40:526–35
   PubMed Web of Science ®Google Scholar
• Bonte F, Parkey R, Graham K, et al. A new method for radionuclide imaging of myocardial infarcts 1. Radiology 1974;110:473–4
   PubMed Web of Science ®Google Scholar
• Khaw B, Gold HK, Yasuda T, et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation 1986;74:501–8
   PubMed Web of Science ®Google Scholar
• Khaw BA, Yasuda T, Gold HK, et al. Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab. J Nucl Med: Official Publication Soc Nucl Med 1987;28:1671–8
   PubMed Web of Science ®Google Scholar
• Okada DR, Johnson G, Liu Z, et al. Early detection of infarct in reperfused canine myocardium using 99mTc-glucarate. J Nucl Med 2004;45:655–64
   PubMed Web of Science ®Google Scholar
• Liu Z, Barrett HH, Stevenson GD, et al. High-resolution imaging with 99mTc-glucarate for assessing myocardial injury in rat heart models exposed to different durations of ischemia with reperfusion. J Nucl Med 2004;45:1251–9
   PubMed Web of Science ®Google Scholar
• Orlandi C, Crane PD, Edwards DS, et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl Med: Official Publication Soc Nucl Med 1991;32:263–8
   PubMed Web of Science ®Google Scholar
• Dasari M, Lee S, Sy J, et al. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Org Lett 2010;12:3300–3
   PubMed Web of Science ®Google Scholar
• Fonge H, Chitneni SK, Lixin J, et al. Necrosis avidity of 99mTc (CO)3-labeled pamoic acid derivatives: synthesis and preliminary biological evaluation in animal models of necrosis. Bioconjugate Chem 2007;18:1924–34
   PubMed Web of Science ®Google Scholar
• Ni Y, Huyghe D, Verbeke K, et al. First preclinical evaluation of mono-[123I] iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 2006;33:595–601
   PubMed Web of Science ®Google Scholar
• Fonge H, Jin L, Wang H, et al. Synthesis and preliminary evaluation of mono-[123I] iodohypericin monocarboxylic acid as a necrosis avid imaging agent. Bioorg Med Chem Lett 2007;17:4001–5
   PubMed Web of Science ®Google Scholar
• Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci 2010;11:562–94
   PubMed Web of Science ®Google Scholar
• Bánó G, Staničová J, Jancura D, et al. On the diffusion of hypericin in dimethylsulfoxide/water mixtures – the effect of aggregation. J Phys Chem B 2011;115:2417–23
   PubMed Web of Science ®Google Scholar
• Van De Putte M, Roskams T, Bormans G, et al. The impact of aggregation on the biodistribution of hypericin. Int J Oncol 2006;28:655–60
   PubMed Web of Science ®Google Scholar
• Fonge H, Vunckx K, Wang H, et al. Non-invasive detection and quantification of acute myocardial infarction in rabbits using MONO-[123I] iodohypericin µSPECT. Eur Heart J 2008;29:260–9
   PubMed Web of Science ®Google Scholar
• Stoll A, Becker B. Sennosides A and B, the active principles of senna. Fortschritte der chemie organischer naturstoffe/progress in the chemistry of organic natural products/progrès dans la chimie des substances organiques naturelles. Germany: Springer; 1950
   Google Scholar
• Ji Y, Zhan Y, Jiang C, et al. Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. J Drug Target 2013;22:304–12
   PubMed Web of Science ®Google Scholar
• Kong M, Zhang J, Jiang C, et al. Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis. J Drug Target 2013;21:604–10
   PubMed Web of Science ®Google Scholar
• Falk H, Meyer J. On the homo-and heteroassociation of hypericin. Monatsh Chem Chem Mon 1994;125:753–62
   Web of Science ®Google Scholar
• Falk H. From the photosensitizer hypericin to the photoreceptor stentorin – the chemistry of phenanthroperylene quinones. Angew Chem Int Ed 1999;38:3116–36
   PubMed Web of Science ®Google Scholar
• Arabei S, Pavich T, Galaup J-P, Jardon P. Influence of the nature of sol–gel matrices on absorption and fine-structure fluorescence spectra of hypericin. Chem Phys Lett 1999;306:303–13
   Web of Science ®Google Scholar
• Lajos G, Jancura D, Miskovsky P, et al. Surface-enhanced fluorescence and Raman scattering study of antitumoral drug hypericin: an effect of aggregation and self-spacing depending on pH. J Phys Chem C 2008;112:12974–80
   Web of Science ®Google Scholar
• Pietrzak M, Maciejczyk M, Szabelski M, et al. Self-association of hypericin analyzed by light absorption and fluorescence spectroscopy and molecular dynamics simulations. Chem Phys Lett 2014;601:39–44
   Web of Science ®Google Scholar
• Cona MM, Alpizar YA, Li J, et al. Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. Pharm Res 2014;31:278–90
   PubMed Web of Science ®Google Scholar
• Fonge H, Van de Putte M, Huyghe D, et al. Evaluation of tumor affinity of mono-[123I] iodohypericin and mono-[123I] iodoprotohypericin in a mouse model with a RIF-1 tumor. Contrast Media Mol Imaging 2007;2:113–19
   PubMed Web of Science ®Google Scholar
• Bormans G, Huyghe D, Christiaen A, et al. Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin. J Labelled Comp Radiopharm 2004;47:191–8
   Web of Science ®Google Scholar
• Prinsen K, Li J, Vanbilloen H, et al. Development and evaluation of a 68Ga labeled pamoic acid derivative for in vivo visualization of necrosis using positron emission tomography. Bioorg Med Chem 2010;18:5274–81
   PubMed Web of Science ®Google Scholar
• Prinsen K, Jin L, Vunckx K, et al. Radiolabeling and preliminary biological evaluation of a 99mTc(CO)3 labeled 3, 3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) derivative as a potential SPECT tracer for in vivo visualization of necrosis. Bioorg Med Chem Lett 2011;21:502–5
   PubMed Web of Science ®Google Scholar